SCHEMBL16446805

SCHEMBL16446805

COc1ccc(-c2nc(O)c3c(n2)NCC3)cc1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4B Q07343 2/20 0.44
▸ PDGFRB P09619 1/20 0.41
▸ PDGFRA P16234 1/20 0.41
▸ MAPK9 P45984 1/20 0.40
▸ MAPKAPK2 P49137 1/20 0.40
▸ RAB9A P51151 4/20 0.40
▸ NPC1 O15118 3/20 0.40
▸ ALDH1A1 P00352 3/20 0.40
▸ SMN1; SMN2 Q16637 3/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ CYP17A1 P05093 1/20 0.40
▸ CYP3A4 P08684 2/20 0.39
▸ CYP11B1 P15538 2/20 0.39
▸ CYP11B2 P19099 2/20 0.39
▸ NCOA1 Q15788 1/20 0.39
▸ NCOA3 Q9Y6Q9 1/20 0.39
▸ ERN1 O75460 1/20 0.38
▸ KDM4E B2RXH2 2/20 0.37
▸ MGLL Q99685 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16446820 0.85 PDE4B (0.53) PDE4BPDGFRBPDGFRAMAPK9MAPKAPK2
SCHEMBL16446615 0.79 PDE4B (0.38) PDE4BPDGFRBPDGFRAMAPK9MAPKAPK2
SCHEMBL13932760 0.73 HTR2C (0.38) PDE4BPDGFRBPDGFRARAB9ANPC1
SCHEMBL16179749 0.72 PDE4B (0.41) PDE4BPDGFRBPDGFRARAB9ANPC1
SCHEMBL16446681 0.69 TDP2 (0.50) PDE4BPDGFRBPDGFRARAB9ANPC1
SCHEMBL5031343 0.68 RAB9A (0.57) PDGFRBPDGFRARAB9ANPC1ALDH1A1
Ammonia Solution, Strong SCHEMBL16446629 0.68 TDP2 (0.49) PDE4BPDGFRBPDGFRARAB9ANPC1
SCHEMBL19876623 0.68 PDGFRB (0.55) PDGFRBPDGFRARAB9ANPC1ALDH1A1
SCHEMBL6075610 0.68 MAPK1 (0.52) PDE4BALDH1A1SMN1; SMN2CYP3A4KDM4E
SCHEMBL5733001 0.68 HSD17B10 (0.49) PDE4BALDH1A1SMN1; SMN2KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3030565-B1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS GRUENENTHAL GMBH (DE) 2017-07-19 — — EP disclosed
US-9688683-B2 Substituted condensed pyrimidine compounds Grünenthal GmbH (DE) 2017-06-27 — — US disclosed
EP-3030565-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2016-06-15 — — EP disclosed
US-20160152624-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2016-06-02 — — US disclosed
WO-2015018534-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2015-02-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160152624-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS PDE4A, PDE4B, TYMP PDE4B 2/4885PDGFRB 1391/4885PDGFRA 1514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback